Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

This is a randomized, open-label, superiority, multicenter clinical trial for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer. It aims to compare the efficacy of neoadjuvant treatment with 2 cycles of Pyrotinib + Trastuzumab + Docetaxel followed by 2 cycles of Pertuzumab + Trastuzumab + Docetaxel versus 4 cycles of Pertuzumab + Trastuzumab + Docetaxel. Exploratory analyses of ctDNA clearance rate and MRI response will also be conducted.

Trial Details

NCT ID
NCT07797218
Phase
PHASE3
Sponsor
Shanghai Jiao Tong University School of Medicine
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Docetaxel
  • Pyrotinib
  • Trastuzumab (Herceptin)
  • Pertuzumab
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Signed informed consent.
  • Age: Female patients aged 18-70 years.
  • Breast cancer meeting the following criteria:
  • Histologically confirmed invasive breast cancer, with primary tumor diameter ≥ 2.0 cm, Stage II-III as assessed by local standard methods.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →